Literature DB >> 17654907

Design of respiration averaged CT for attenuation correction of the PET data from PET/CT.

Pai-Chun Melinda Chi1, Osama Mawlawi, Sadek A Nehmeh, Yusuf E Erdi, Peter A Balter, Dershan Luo, Radhe Mohan, Tinsu Pan.   

Abstract

Our previous patient studies have shown that the use of respiration averaged computed tomography (ACT) for attenuation correction of the positron emission tomography (PET) data from PET/CT reduces the potential misalignment in the thorax region by matching the temporal resolution of the CT to that of the PET. In the present work, we investigated other approaches of acquiring ACT in order to reduce the CT dose and to improve the ease of clinical implementation. Four-dimensional CT (4DCT) data sets for ten patients (17 lung/esophageal tumors) were acquired in the thoracic region immediately after the routine PET/CT scan. For each patient, multiple sets of ACTs were generated based on both phase image averaging (phase approach) and fixed cine duration image averaging (cine approach). In the phase approach, the ACTs were calculated from CT images corresponding to the significant phases of the respiratory cycle: ACT(050phs) from end-inspiration (0%) and end-expiration (50%), ACT(2070phs) from mid-inspiration (20%) and mid-expiration (70%), ACT(4phs) from 0%, 20%, 50% and 70%, and ACT(10phs) from all ten phases, which was the original approach. In the cine approach, which does not require 4DCT, the ACTs were calculated based on the cine images from cine durations of 1 to 6 s at 1 s increments. PET emission data for each patient were attenuation corrected with each of the above mentioned ACTs and the tumor maximum standard uptake value (SUVmax), average SUV (SUVavg), and tumor volume measurements were compared. Percent differences were calculated between PET data corrected with various ACTs and that corrected with ACT(10phs). In the phase approach, the ACT(10phs) can be approximated by the ACT(4phs) to within a mean percent difference of 2% in SUV and tumor volume measurements. In cine approach, ACT(10phs) can be approximated to within a mean percent difference of 3% by ACTs computed from cine durations > or =3 s. Acquiring CT images only at the four significant phases for the ACT can reduce radiation dose to 1/3 of the current 4DCT dose; however, the implementation of this approach requires additional hardware that is not standard equipment on PET/CT scanners. In the cine approach, we recommend a duration of 6 +/- 1 s in order to include variations of respiratory patterns in a larger population. This approach can be easily implemented because cine acquisition mode is available on all GE PET/CT scanners. The CT dose in the cine approach can be reduced to approximately 5 mGy by using the lowest mA setting (10 mA), while still maintaining good quality CT data for PET attenuation correction. In our scanning protocol, the ACT is only acquired if respiration-induced misregistration is observed (determined before the PET scan is completed), and therefore patients do not receive unnecessary CT radiation dose.

Entities:  

Mesh:

Year:  2007        PMID: 17654907     DOI: 10.1118/1.2733810

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  13 in total

1.  Respiratory motion handling is mandatory to accomplish the high-resolution PET destiny.

Authors:  Doumit Daou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-12       Impact factor: 9.236

2.  Classification and evaluation strategies of auto-segmentation approaches for PET: Report of AAPM task group No. 211.

Authors:  Mathieu Hatt; John A Lee; Charles R Schmidtlein; Issam El Naqa; Curtis Caldwell; Elisabetta De Bernardi; Wei Lu; Shiva Das; Xavier Geets; Vincent Gregoire; Robert Jeraj; Michael P MacManus; Osama R Mawlawi; Ursula Nestle; Andrei B Pugachev; Heiko Schöder; Tony Shepherd; Emiliano Spezi; Dimitris Visvikis; Habib Zaidi; Assen S Kirov
Journal:  Med Phys       Date:  2017-05-18       Impact factor: 4.071

3.  Ultra-low dose CT attenuation correction for PET/CT.

Authors:  Ting Xia; Adam M Alessio; Bruno De Man; Ravindra Manjeshwar; Evren Asma; Paul E Kinahan
Journal:  Phys Med Biol       Date:  2011-12-09       Impact factor: 3.609

Review 4.  Advances in 4D radiation therapy for managing respiration: part I - 4D imaging.

Authors:  Geoffrey D Hugo; Mihaela Rosu
Journal:  Z Med Phys       Date:  2012-07-10       Impact factor: 4.820

5.  Dose calculation with respiration-averaged CT processed from cine CT without a respiratory surrogate.

Authors:  Adam C Riegel; Moiz Ahmad; Xiaojun Sun; Tinsu Pan
Journal:  Med Phys       Date:  2008-12       Impact factor: 4.071

Review 6.  Morphology supporting function: attenuation correction for SPECT/CT, PET/CT, and PET/MR imaging.

Authors:  Tzu C Lee; Adam M Alessio; Robert M Miyaoka; Paul E Kinahan
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-11-17       Impact factor: 2.346

7.  Respiration-averaged CT for attenuation correction in non-small-cell lung cancer.

Authors:  Nai-Ming Cheng; Chih-Teng Yu; Kung-Chu Ho; Yi-Cheng Wu; Yuan-Chang Liu; Chih-Wei Wang; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-03       Impact factor: 9.236

8.  Effects of respiration-averaged computed tomography on positron emission tomography/computed tomography quantification and its potential impact on gross tumor volume delineation.

Authors:  Pai-Chun Melinda Chi; Osama Mawlawi; Dershan Luo; Zhongxing Liao; Homer A Macapinlac; Tinsu Pan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-07-01       Impact factor: 7.038

9.  Cine computed tomography without respiratory surrogate in planning stereotactic radiotherapy for non-small-cell lung cancer.

Authors:  Adam C Riegel; Joe Y Chang; Sastry S Vedam; Valen Johnson; Pai-Chun Melinda Chi; Tinsu Pan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-07-19       Impact factor: 7.038

10.  Effect of Non-Alignment/Alignment of Attenuation Map Without/With Emission Motion Correction in Cardiac SPECT/CT.

Authors:  Joyoni Dey; W Paul Segars; P Hendrik Pretorius; Michael A King
Journal:  IEEE Trans Nucl Sci       Date:  2015-07-23       Impact factor: 1.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.